- Home
- PLBC vs CLLS Comparison
PLBC vs CLLS Comparison
Compare PLBC & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLBC
- CLLS
- Stock Information
- Founded
- PLBC 1980
- CLLS 1999
- Country
- PLBC United States
- CLLS France
- Employees
- PLBC N/A
- CLLS N/A
- Industry
- PLBC Finance Companies
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- PLBC Finance
- CLLS Health Care
- Exchange
- PLBC Nasdaq
- CLLS Nasdaq
- Market Cap
- PLBC 236.7M
- CLLS 299.0M
- IPO Year
- PLBC 2005
- CLLS 2007
- Fundamental
- Price
- PLBC $43.33
- CLLS $3.08
- Analyst Decision
- PLBC Buy
- CLLS Buy
- Analyst Count
- PLBC 4
- CLLS 1
- Target Price
- PLBC $57.00
- CLLS $4.00
- AVG Volume (30 Days)
- PLBC 12.5K
- CLLS 71.4K
- Earning Date
- PLBC 10-15-2025
- CLLS 11-03-2025
- Dividend Yield
- PLBC 2.65%
- CLLS N/A
- EPS Growth
- PLBC 1.22
- CLLS N/A
- EPS
- PLBC 4.86
- CLLS N/A
- Revenue
- PLBC $84,003,000.00
- CLLS $63,438,000.00
- Revenue This Year
- PLBC $22.16
- CLLS N/A
- Revenue Next Year
- PLBC $17.58
- CLLS $66.76
- P/E Ratio
- PLBC $9.33
- CLLS N/A
- Revenue Growth
- PLBC 6.85
- CLLS 223.09
- 52 Week Low
- PLBC $37.69
- CLLS $1.10
- 52 Week High
- PLBC $51.33
- CLLS $3.35
- Technical
- Relative Strength Index (RSI)
- PLBC 48.99
- CLLS 62.30
- Support Level
- PLBC $42.97
- CLLS $2.88
- Resistance Level
- PLBC $46.59
- CLLS $3.20
- Average True Range (ATR)
- PLBC 0.97
- CLLS 0.17
- MACD
- PLBC -0.12
- CLLS 0.02
- Stochastic Oscillator
- PLBC 19.90
- CLLS 68.24
About PLBC Plumas Bancorp
Plumas Bancorp provides various banking products and services in Northeastern California and Northwestern Nevada. It provides various deposit products such as checking, interest-bearing checking, business sweep, public funds sweep, savings, time deposit, and retirement accounts. The bank's loan portfolio consists of commercial real estate loans; commercial and industrial loans; consumer loans; agricultural loans; residential real estate loans, and construction and land development loans. The bank generates revenue from loans and investment securities in its portfolio and, to a lesser extent, service fees.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.